Pharmaceutical

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “We are focused on preparing for our upcoming meeting with the FDA to discuss the points identified in the CRL and a potential …

Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today reported financial results for the three months and year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“We are focused on preparing for our upcoming meeting with the FDA to discuss the points identified in the CRL and a potential path forward for the approval of Twirla,” stated Al Altomari, Chairman and Chief Executive Officer of Agile. “We believe that Twirla, if approved, will provide women with a new contraceptive option in the form of a patch that is designed to deliver a low dose of estrogen and offer greater convenience for women.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20595.89+4.91
TSXV846.29-0.92
DOW34168.09-129.64
S&P 5004349.93-6.52
NASD13542.12+2.82
ASX6961.60-177.90

COMMODITIES

Commodities
Gold1815.27-6.60
Silver23.26-0.31
Copper4.44-0.07
Palladium2316.99-2.02
Platinum1023.32-11.39
Oil86.74-0.61
Heating Oil2.68-0.01
Natural Gas4.26-0.02

DOWNLOAD FREE REPORTS

×